Acer Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.37179 million. Net loss was USD 14.73 million compared to USD 5.01 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.31 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 0.31 a year ago.
For the nine months, sales was USD 0.37179 million. Net loss was USD 39.1 million compared to USD 16.85 million a year ago. Basic loss per share from continuing operations was USD 1.68 compared to USD 1.11 a year ago. Diluted loss per share from continuing operations was USD 1.68 compared to USD 1.13 a year ago.